Login to Your Account

Xenikos’ conjugated antibody cocktail makes inroads against GvHD

By Cormac Sheridan
Staff Writer

Thursday, May 26, 2016

DUBLIN – Xenikos BV is on track to complete recruitment in a phase I/II trial of T-Guard, a combination of two antibody-drug conjugates in development for treating steroid refractory graft-vs.-host disease (GvHD), in the coming months.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription